Cargando…

Molecular targeted therapy of BRAF-mutant colorectal cancer

Over the past two decades, the molecular characterization of metastatic colorectal cancer (mCRC) has been revolutionized by the routine implementation of RAS and BRAF tests. As a result, it is now known that patients with mCRC harboring BRAF mutations experience a poor prognosis. Although it account...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ducreux, Michel, Chamseddine, Ali, Laurent-Puig, Pierre, Smolenschi, Cristina, Hollebecque, Antoine, Dartigues, Peggy, Samallin, Emmanuelle, Boige, Valérie, Malka, David, Gelli, Maximiliano
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6582307/ https://www.ncbi.nlm.nih.gov/pubmed/31244912 http://dx.doi.org/10.1177/1758835919856494

Ejemplares similares

Immunotherapy and Hepatocellular Cancer: Where Are We Now?
por: Valery, Marine, et al.
Publicado: (2022)

Immunotherapy in Advanced Biliary Tract Cancers
por: Boilève, Alice, et al.
Publicado: (2021)

Implementing patient derived organoids in functional precision medicine for patients with advanced colorectal cancer
por: Cartry, Jérôme, et al.
Publicado: (2023)

Primary Colorectal Tumor Displays Differential Genomic Expression Profiles Associated with Hepatic and Peritoneal Metastases
por: Gelli, Maximiliano, et al.
Publicado: (2023)

Precision Medicine in Pancreatic Ductal Adenocarcinoma: The Impact of Targeted Therapies on Survival of Patients Harboring Actionable Mutations
por: Tarabay, Anthony, et al.
Publicado: (2023)

Targetable Molecular Alterations in the Treatment of Biliary Tract Cancers: An Overview of the Available Treatments
por: Valery, Marine, et al.
Publicado: (2023)

Postoperative hepatic arterial chemotherapy in high-risk patients as adjuvant treatment after resection of colorectal liver metastases - a randomized phase II/III trial – PACHA-01 (NCT02494973)
por: Goéré, Diane, et al.
Publicado: (2018)

No evidence for changes in skeletal muscle mass or weight during first-line chemotherapy for metastatic colorectal cancer
por: Antoun, Sami, et al.
Publicado: (2019)

Exploring the best treatment options for BRAF-mutant metastatic colon cancer
por: Taieb, Julien, et al.
Publicado: (2019)

Targeting mutant BRAF in colorectal cancer
por: Carroll, David, et al.
Publicado: (2013)

Tumour-infiltrating CD68+ and CD57+ cells predict patient outcome in stage II–III colorectal cancer
por: Chaput, N, et al.
Publicado: (2013)

BRAF Inhibition in BRAF(V600)-Mutant Gliomas: Results From the VE-BASKET Study
por: Kaley, Thomas, et al.
Publicado: (2018)

Safety and Efficacy of Bevacizumab in Cancer Patients with Inflammatory Bowel Disease
por: Herrera-Gómez, Ruth Gabriela, et al.
Publicado: (2022)

Emerging treatment options for BRAF-mutant colorectal cancer
por: Ursem, Carling, et al.
Publicado: (2018)

Combination drug development in BRAF mutant colorectal cancer
por: Lam, Michael, et al.
Publicado: (2018)

Synergizing liver systemic treatments with interventional oncology: friend or foe?
por: Jost, Raphaël, et al.
Publicado: (2022)

Chromosomal Instability in BRAF Mutant, Microsatellite Stable Colorectal Cancers
por: Bond, Catherine E., et al.
Publicado: (2012)

Current Therapeutic Strategies in BRAF-Mutant Metastatic Colorectal Cancer
por: Grassi, Elisa, et al.
Publicado: (2021)

BRAF associated autophagy exploitation: BRAF and autophagy inhibitors synergise to efficiently overcome resistance of BRAF mutant colorectal cancer cells
por: Goulielmaki, Maria, et al.
Publicado: (2016)

BRAF Inhibitors for BRAF V600E Mutant Colorectal Cancers: Literature Survey and Case Report
por: Peker, Yasar Subutay, et al.
Publicado: (2018)

APC Mutation Marks an Aggressive Subtype of BRAF Mutant Colorectal Cancers
por: Fennell, Lochlan J., et al.
Publicado: (2020)

Economic evaluation of encorafenib with cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer in France: a cost-effectiveness analysis using data from the BEACON CRC randomised controlled trial
por: Trouiller, Jean-Baptiste, et al.
Publicado: (2022)

BRAF-mutant hematopoietic malignancies
por: Abdel-Wahab, Omar, et al.
Publicado: (2014)

Paradox breaker BRAF inhibitors have comparable potency and MAPK pathway reactivation to encorafenib in BRAF mutant colorectal cancer
por: Pickles, Oliver J., et al.
Publicado: (2020)

Molecular mechanisms underlying the resistance of BRAF V600E-mutant metastatic colorectal cancer to EGFR/BRAF inhibitors
por: Xu, Ting, et al.
Publicado: (2022)

Variations of BRAF mutant allele percentage in melanomas
por: Hélias-Rodzewicz, Zofia, et al.
Publicado: (2015)

Identification of anticancer drugs to radiosensitise BRAF-wild-type and mutant colorectal cancer
por: Carter, Rebecca, et al.
Publicado: (2019)

Real‐world treatment and outcomes of patients with metastatic BRAF mutant colorectal cancer
por: Xu, Ting, et al.
Publicado: (2023)

Efficacy of BRAF and MEK Inhibition in Patients with BRAF-Mutant Advanced Melanoma and Germline CDKN2A Pathogenic Variants
por: Spagnolo, Francesco, et al.
Publicado: (2021)

Response to BRAF-targeted Therapy Is Enhanced by Cotargeting VEGFRs or WNT/β-Catenin Signaling in BRAF-mutant Colorectal Cancer Models
por: Tran, Khanh B., et al.
Publicado: (2022)

BET and BRAF inhibitors act synergistically against BRAF‐mutant melanoma
por: Paoluzzi, Luca, et al.
Publicado: (2016)

Medical debulking with BRAF/MEK inhibitors in aggressive BRAF-mutant craniopharyngioma
por: Di Stefano, Anna Luisa, et al.
Publicado: (2020)

Clinical and prognostic features of patients with detailed RAS/BRAF-mutant colorectal cancer in Japan
por: Ikoma, Tatsuki, et al.
Publicado: (2021)

The Evolutionary Landscape of Treatment for BRAF(V600E) Mutant Metastatic Colorectal Cancer
por: Mauri, Gianluca, et al.
Publicado: (2021)

RNF43 is associated with genomic features and clinical outcome in BRAF mutant colorectal cancer
por: Shang, Peipei, et al.
Publicado: (2023)

Optimizing the treatment of BRAF mutant melanoma
por: Settleman, Jeff
Publicado: (2014)

Dabrafenib for treatment of BRAF-mutant melanoma
por: Kainthla, Radhika, et al.
Publicado: (2013)

BRAF mutant colorectal cancer: ErbB2 expression levels as predictive factor for the response to combined BRAF/ErbB inhibitors
por: Miele, Evelina, et al.
Publicado: (2020)

Acquired resistance to BRAF inhibition in BRAF(V600E) mutant gliomas
por: Yao, Tsun-Wen, et al.
Publicado: (2016)

Development of small-molecule therapeutics and strategies for targeting RAF kinase in BRAF-mutant colorectal cancer
por: Pan, Jing-hua, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_4fermn2mn6q3dkj5896mbrlqeg